The Pathology of Drug-Induced Liver Injury

 

 Buy Article Permissions and Reprints

ABSTRACT

The liver biopsy is frequently used as an adjunct diagnostic test in the evaluation of drug-induced liver injury (DILI). A biopsy may be performed to confirm the diagnosis, especially when there is a complex clinical differential diagnosis that includes DILI. A biopsy can also be used to stage the severity of hepatotoxicity so that a necessary agent may be continued. Alternatively, a drug or toxin may only be implicated after a biopsy is performed, particularly in the case of subacute or chronic liver injury. The pathologist should approach the biopsy systematically by first classifying the disease and then working with the clinician to include or exclude etiologies in the pathological differential diagnosis. This article outlines a practical approach to the diagnosis of DILI on liver biopsy, including the common patterns of injury observed in drug- and toxin-induced liver pathology and prognostic pathological features that may be associated with the outcome of patients with DILI.

REFERENCES

• 1 Lasser K E, Allen P D, Woolhandler S J, Himmelstein D U, Wolfe S M, Bor D H. Timing of new black box warnings and withdrawals for prescription medications.  JAMA. 2002;  287(17) 2215-2220
  CrossrefPubMedGoogle Scholar
• 2 McKenzie R, Fried M W, Sallie R et al.. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B.  N Engl J Med. 1995;  333(17) 1099-1105
  CrossrefPubMedGoogle Scholar
• 3 Farrell G C. Drug-Induced Liver Disease. Edinburgh, UK; Churchill Livingstone 1994
  PubMedGoogle Scholar
• 4 Snover D C. Drug-Induced Liver Disease. Biopsy Diagnosis of Liver Disease. Baltimore, MD; Williams and Wilkins 1992: 164-177
  PubMedGoogle Scholar
• 5 Stricker B HC. Drug-Induced Hepatic Injury. 2nd ed. Amsterdam, The Netherlands; Elsevier Science 1992
  PubMedGoogle Scholar
• 6 Zimmerman H J. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. 2nd ed. Philadelphia, PA; Lippincott, Williams & Wilkins 1999
  PubMedGoogle Scholar
• 7 Lewis J H, Kleiner D E. Hepatic injury due to drugs, chemicals and toxins. In: Burt AD, Portmann BC, Ferrell LD MacSween's Pathology of the Liver. Philadelphia, PA; Elsevier 2007: 649-759
  PubMedGoogle Scholar
• 8 Kleiner D E, Gaffey M J, Sallie R et al.. Histopathologic changes associated with fialuridine hepatotoxicity.  Mod Pathol. 1997;  10(3) 192-199
  PubMedGoogle Scholar
• 9 Chariot P, Drogou I, de Lacroix-Szmania I et al.. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion.  J Hepatol. 1999;  30(1) 156-160
  CrossrefPubMedGoogle Scholar
• 10 Lai K K, Gang D L, Zawacki J K, Cooley T P. Fulminant hepatic failure associated with 2′,3′-dideoxyinosine (ddI).  Ann Intern Med. 1991;  115(4) 283-284
  PubMedGoogle Scholar
• 11 Lewis W, Levine E S, Griniuviene B et al.. Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts.  Proc Natl Acad Sci U S A. 1996;  93(8) 3592-3597
  CrossrefPubMedGoogle Scholar
• 12 Roenigk Jr H H, Auerbach R, Maibach H I, Weinstein G D. Methotrexate in psoriasis: revised guidelines.  J Am Acad Dermatol. 1988;  19(1 Pt 1) 145-156
  CrossrefPubMedGoogle Scholar
• 13 Khan S, Subedi D, Chowdhury M M. Use of amino terminal type III procollagen peptide (P3NP) assay in methotrexate therapy for psoriasis.  Postgrad Med J. 2006;  82(967) 353-354
  CrossrefPubMedGoogle Scholar
• 14 Zachariae H, Heickendorff L, Søgaard H. The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10-year follow-up.  Br J Dermatol. 2001;  144(1) 100-103
  CrossrefPubMedGoogle Scholar
• 15 Akhtar M A, Mathieson K, Arey B et al.. Hepatic histopathology and clinical characteristics associated with antiretroviral therapy in HIV patients without viral hepatitis.  Eur J Gastroenterol Hepatol. 2008;  20(12) 1194-1204
  CrossrefPubMedGoogle Scholar
• 16 Borghi V, Puoti M, Mussini C et al.. HIV coinfection and antiretroviral therapy enhances liver steatosis in patients with hepatitis C, but only in those infected by HCV genotype other than 3.  Antivir Ther. 2008;  13(8) 1057-1065
  PubMedGoogle Scholar
• 17 Kleiner D E, Chalasani N P, Conjeevaram H S et al.. Relationship of biochemical to histologic findings and the pathological pattern of injury among cases identified in the NIH Drug-Induced Liver Injury Network (DILIN) study.  Gastroenterology. 2007;  132 A773
  PubMedGoogle Scholar
• 18 Popper H, Rubin E, Cardiol D, Schaffner F, Paronetto F. Drug-induced liver disease: a penalty for progress.  Arch Intern Med. 1965;  115 128-136
  PubMedGoogle Scholar
• 19 Edmondson H A, Henderson B, Benton B. Liver-cell adenomas associated with use of oral contraceptives.  N Engl J Med. 1976;  294(9) 470-472
  CrossrefPubMedGoogle Scholar
• 20 Ishak K G. Hepatic neoplasms associated with contraceptive and anabolic steroids.  Recent Results Cancer Res. 1979;  66 73-128
  PubMedGoogle Scholar
• 21 Mays E T, Christopherson W. Hepatic tumors induced by sex steroids.  Semin Liver Dis. 1984;  4(2) 147-157
  Article in Thieme ConnectPubMedGoogle Scholar
• 22 Suh N, Liapis H, Misdraji J, Brunt E M, Wang H L. Epstein-Barr virus hepatitis: diagnostic value of in situ hybridization, polymerase chain reaction, and immunohistochemistry on liver biopsy from immunocompetent patients.  Am J Surg Pathol. 2007;  31(9) 1403-1409
  CrossrefPubMedGoogle Scholar
• 23 Suriawinata A A, Thung S N. Acute and chronic hepatitis.  Semin Diagn Pathol. 2006;  23(3-4) 132-148
  CrossrefPubMedGoogle Scholar
• 24 Kleiner D E. Granulomas in the liver.  Semin Diagn Pathol. 2006;  23(3-4) 161-169
  CrossrefPubMedGoogle Scholar
• 25 Medline A, Cohen L B, Tobe B A, Sellers E M. Liver granulomas and allopurinol.  BMJ. 1978;  1(6123) 1320-1321
  CrossrefPubMedGoogle Scholar
• 26 Mullick F G, Ishak K G. Hepatic injury associated with diphenylhydantoin therapy. A clinicopathologic study of 20 cases.  Am J Clin Pathol. 1980;  74(4) 442-452
  PubMedGoogle Scholar
• 27 Cook I F, Shilkin K B, Reed W D. Phenytoin induced granulomatous hepatitis.  Aust N Z J Med. 1981;  11(5) 539-541
  PubMedGoogle Scholar
• 28 Propst A, Propst T, Dietze O, Kathrein H, Judmeier G, Vogel W. Development of granulomatous hepatitis during treatment with interferon-alpha 2b.  Dig Dis Sci. 1995;  40(10) 2117-2118
  CrossrefPubMedGoogle Scholar
• 29 Ishak K G. Hepatic lesions caused by anabolic and contraceptive steroids.  Semin Liver Dis. 1981;  1(2) 116-128
  Article in Thieme ConnectPubMedGoogle Scholar
• 30 Lewis J H, Zimmerman H J. Drug- and chemical-induced cholestasis.  Clin Liver Dis. 1999;  3(3) 433-464, vii
  CrossrefPubMedGoogle Scholar
• 31 Doria Jr M I, Shepard K V, Levin B, Riddell R H. Liver pathology following hepatic arterial infusion chemotherapy. Hepatic toxicity with FUDR.  Cancer. 1986;  58(4) 855-861
  CrossrefPubMedGoogle Scholar
• 32 Ludwig J, Kim C H, Wiesner R H, Krom R A. Floxuridine-induced sclerosing cholangitis: an ischemic cholangiopathy?.  Hepatology. 1989;  9(2) 215-218
  CrossrefPubMedGoogle Scholar
• 33 Desmet V J. Vanishing bile duct syndrome in drug-induced liver disease.  J Hepatol. 1997;  26(Suppl 1) 31-35
  CrossrefPubMedGoogle Scholar
• 34 Ludwig J, Wiesner R H, LaRusso N F. Idiopathic adulthood ductopenia. A cause of chronic cholestatic liver disease and biliary cirrhosis.  J Hepatol. 1988;  7(2) 193-199
  CrossrefPubMedGoogle Scholar
• 35 Brunt E M. Nonalcoholic steatohepatitis.  Semin Liver Dis. 2004;  24(1) 3-20
  Article in Thieme ConnectPubMedGoogle Scholar
• 36 Lewis J H, Mullick F, Ishak K G et al.. Histopathologic analysis of suspected amiodarone hepatotoxicity.  Hum Pathol. 1990;  21(1) 59-67
  CrossrefPubMedGoogle Scholar
• 37 Murata Y, Ogawa Y, Saibara T et al.. Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients.  Oncol Rep. 2000;  7(6) 1299-1304
  PubMedGoogle Scholar
• 38 Bissuel F, Bruneel F, Habersetzer F et al.. Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.  J Intern Med. 1994;  235(4) 367-371
  CrossrefPubMedGoogle Scholar
• 39 DeLeve L D, Shulman H M, McDonald G B. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease).  Semin Liver Dis. 2002;  22(1) 27-42
  Article in Thieme ConnectPubMedGoogle Scholar
• 40 Nakanuma Y, Tsuneyama K, Ohbu M, Katayanagi K. Pathology and pathogenesis of idiopathic portal hypertension with an emphasis on the liver.  Pathol Res Pract. 2001;  197(2) 65-76
  CrossrefPubMedGoogle Scholar
• 41 McDonald G B, Hinds M S, Fisher L D et al.. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients.  Ann Intern Med. 1993;  118(4) 255-267
  CrossrefPubMedGoogle Scholar
• 42 Geller S A, Dubinsky M C, Poordad F F et al.. Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease.  Am J Surg Pathol. 2004;  28(9) 1204-1211
  CrossrefPubMedGoogle Scholar
• 43 Lewis J H, Tice H L, Zimmerman H J. Budd-Chiari syndrome associated with oral contraceptive steroids. Review of treatment of 47 cases.  Dig Dis Sci. 1983;  28(8) 673-683
  CrossrefPubMedGoogle Scholar
• 44 Lefkowitch J H, Lobritto S J, Brown Jr R S et al.. Ground-glass, polyglucosan-like hepatocellular inclusions: a “new” diagnostic entity.  Gastroenterology. 2006;  131(3) 713-718
  CrossrefPubMedGoogle Scholar
• 45 Vazquez J J, Guillen F J, Zozaya J, Lahoz M. Cyanamide-induced liver injury. A predictable lesion.  Liver. 1983;  3(4) 225-230
  PubMedGoogle Scholar
• 46 Torbenson M, Chen Y Y, Brunt E et al.. Glycogenic hepatopathy: an underrecognized hepatic complication of diabetes mellitus.  Am J Surg Pathol. 2006;  30(4) 508-513
  CrossrefPubMedGoogle Scholar
• 47 Iancu T C, Shiloh H, Dembo L. Hepatomegaly following short-term high-dose steroid therapy.  J Pediatr Gastroenterol Nutr. 1986;  5(1) 41-46
  CrossrefPubMedGoogle Scholar
• 48 Goodman Z D. Drug hepatotoxicity.  Clin Liver Dis. 2002;  6(2) 381-397
  CrossrefPubMedGoogle Scholar
• 49 Björnsson E, Kalaitzakis E, Olsson R. The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury.  Aliment Pharmacol Ther. 2007;  25(12) 1411-1421
  CrossrefPubMedGoogle Scholar
• 50 Benjamin S B, Goodman Z D, Ishak K G, Zimmerman H J, Irey N S. The morphologic spectrum of halothane-induced hepatic injury: analysis of 77 cases.  Hepatology. 1985;  5(6) 1163-1171
  CrossrefPubMedGoogle Scholar
• 51 Donaldson B W, Gopinath R, Wanless I R et al.. The role of transjugular liver biopsy in fulminant liver failure: relation to other prognostic indicators.  Hepatology. 1993;  18(6) 1370-1376
  CrossrefPubMedGoogle Scholar
• 52 Katoonizadeh A, Nevens F, Verslype C, Pirenne J, Roskams T. Liver regeneration in acute severe liver impairment: a clinicopathological correlation study.  Liver Int. 2006;  26(10) 1225-1233
  CrossrefPubMedGoogle Scholar
• 53 Vuppalanchi R, Chalasani N, Saxena R. Restoration of bile ducts in drug-induced vanishing bile duct syndrome due to zonisamide.  Am J Surg Pathol. 2006;  30(12) 1619-1623
  CrossrefPubMedGoogle Scholar

David E KleinerM.D. Ph.D. 

Laboratory of Pathology/NCI, Bldg. 10, Room 2B50, MSC 1500, 10 Center Drive

Bethesda, MD 20892

Email: kleinerd@mail.nih.gov